Name | SNS-314 Mesylate |
Synonyms | SNS314 SNS 314 SNS-314 Mesylate SNS-314 MESYLATE M1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea Mesylate 1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea methanesulfonate N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate |
CAS | 1146618-41-8 |
Molecular Formula | C19H19ClN6O4S3 |
Molar Mass | 527.03996 |
Solubility | Soluble in DMSO (up to at least 25 mg/ml). |
Appearance | solid |
Color | Off-white |
Storage Condition | -20° |
Stability | Stable for 1 year as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
In vitro study | SNS-314 Mesylate potently inhibited tumor cell lines with an IC50 of 1.8 to 24 nM, independent of the relative Aurora-A or Aurora-B protein levels of the cells. SNS-314 inhibition of histone H3 phosphorylation at the Ser10 site, the HCT116 cell mitosis disorder. Continuous treatment with SNS-314 and Carboplatin, gemitabine, 5-FU, Daunomycin, and SN-38 showed enhanced anti-proliferative effects, and the combination of SNS-314 Mesylate and gemitabine, Docetaxel, or Vincristine showed synergistic effects. |
In vivo study | SNS-314 Mesylate acts on HCT116 colon xenograft and shows significant and long-lasting anti-cancer effect. SNS-314 of the 170 mg/kg dose treated humans for breast cancer (MDA-MB-231), prostate cancer (PC-3), lung cancer (H1299 and Calu-6), ovarian cancer (A2780), and malignant melanoma (A375) the mice transplanted tumor also showed significant anticancer activity, tumor growth inhibition rate was 54 to 91%. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.897 ml | 9.487 ml | 18.974 ml |
5 mM | 0.379 ml | 1.897 ml | 3.795 ml |
10 mM | 0.19 ml | 0.949 ml | 1.897 ml |
5 mM | 0.038 ml | 0.19 ml | 0.379 ml |